<DOC>
	<DOCNO>NCT01529515</DOCNO>
	<brief_summary>The purpose study evaluate efficacy paliperidone palmitate 3 month formulation ( PP3M ) compare placebo delay time first occurrence relapse symptom schizophrenia .</brief_summary>
	<brief_title>A Study Paliperidone Palmitate 3 Month Formulation Treatment Patients With Schizophrenia</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double blind ( neither physician patient know treatment patient receives ) , parallel group ( group patient treat time ) , placebo-controlled ( inactive substance compare drug test whether drug real effect clinical trial ) multicenter study . The study consist 4 phase : Screening Phase ( 3 week ) ; 17-week flexible dose open-label Transition Phase ( open-label phase mean people know identity intervention ) ; 12-week fix dose open-label Maintenance Phase ; randomize , double-blind , fix dose , placebo-controlled relapse prevention phase ( refer Double-blind Phase ) . Patients meet specific stabilization criterion enter Double-blind Phase Week 29 . Patients randomly assign , 1:1 ratio , receive either fix dose PP3M placebo . The Double-blind Phase variable duration ; patient remain study experience relapse event meet discontinuation criterion .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>Patients schizophrenia 1 year A total score Positive Negative Syndrome Scale ( PANSS ) &lt; 120 Signed inform consent Women must pregnant , breastfeed , capable pregnancy must practice effective method birth control Men must agree use doublebarrier method birth control Be medically stable basis clinical laboratory test , physical examination , medical history , vital sign , electrocardiogram ( ECG ) A diagnosis schizophrenia , e.g. , dissociative disorder , bipolar disorder , major depressive disorder , schizoaffective disorder , schizophreniform disorder , autistic disorder , primary substanceinduced psychotic disorder , dementiarelated psychosis Relevant history current presence significant unstable medical condition ( ) determine clinically significant Investigator ( ie , obesity , diabetes , heart disease etc ) A diagnosis substance dependence within 6 month screen History neuroleptic malignant syndrome ( NMS ) tardive dyskinesia Clozapine use last 2 month use treatmentresistant treatmentrefractory illness Clinically significant finding biochemistry , hematology , ECG urinalysis result Any disease condition , opinion investigator , would make participation best interest patient could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>R092670</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Paliperidone palmitate 3 month formulation ( PP3M )</keyword>
</DOC>